Avelumab expanded access program in metastatic Merkel cell carcinoma: efficacy and safety findings from patients in Europe and the Middle East
AuthorsAscierto, P. A.
Chiarion Sileni, V.
Lorigan, Paul C
AffiliationIstituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy.
MetadataShow full item record
AbstractIncidence rates of Merkel cell carcinoma (MCC), an uncommon skin cancer with an aggressive disease course, have increased in recent decades. Limited treatment options are available for patients with metastatic MCC (mMCC). Avelumab, an anti-programmed cell death-ligand 1 monoclonal antibody, became the first approved treatment for mMCC after the results of the phase 2 JAVELIN Merkel 200 study. Prior to its regulatory approval, an expanded access program (EAP) enabled compassionate use of avelumab in patients with mMCC. Here we report findings from patients enrolled in the EAP in Europe and the Middle East. Efficacy and safety data were provided at the discretion of treating physicians. Between March 2, 2016, and December 22, 2018, 403 requests for avelumab were received from 21 countries, and avelumab was supplied to 335 patients. Most patients (96.7%) received avelumab as second-line or later treatment. In 150 patients for whom response data were available, the objective response rate was 48.0%, and in responding patients, median duration of treatment was 7.4 months (range, 1.0-41.7 months). The most common treatment-related adverse events were infusion-related reaction (2.4%) and pyrexia (2.1%), and no new safety signals were observed. Overall, results from European and Middle Eastern patients enrolled in this EAP confirm the efficacy and safety of avelumab treatment observed in previous studies in patients with mMCC.
CitationAscierto PA, Orlova K, Grignani G, Dudzisz‐Śledź M, Fenig E, Chiarion Sileni V, et al. Avelumab expanded access program in metastatic Merkel cell carcinoma: Efficacy and safety findings from patients in Europe and the Middle East. Int J Cancer. 2021 Aug 3.
JournalInternational Journal of Cancer
- Avelumab treatment in Italian patients with metastatic Merkel cell carcinoma: experience from an expanded access program.
- Authors: Grignani G, Chiarion Sileni V, Pinto C, Depenni R, Fazio N, Galli L, Giuffrida D, Carnaghi C, Ciliberto D, Corsi DC, Queirolo P, Benincasa E, Venturini F, Fazzi G, Costa N, Ascierto PA
- Issue date: 2021 Feb 15
- Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma: A Preplanned Interim Analysis of a Clinical Trial.
- Authors: D'Angelo SP, Russell J, Lebbé C, Chmielowski B, Gambichler T, Grob JJ, Kiecker F, Rabinowits G, Terheyden P, Zwiener I, Bajars M, Hennessy M, Kaufman HL
- Issue date: 2018 Sep 1
- Merkel cell carcinoma in Latin America: a contribution from an expanded access program for avelumab to address issues from experts' recommendations.
- Authors: Munhoz RR, Cayol F, Corrales L, Gerson R, Tilli M, Barreto EO, Sánchez Castillo JO, Schmerling RA, Cinat G
- Issue date: 2021 Apr
- Efficacy and safety of avelumab treatment in patients with metastatic Merkel cell carcinoma: experience from a global expanded access program.
- Authors: Walker JW, Lebbé C, Grignani G, Nathan P, Dirix L, Fenig E, Ascierto PA, Sandhu S, Munhoz R, Benincasa E, Flaskett S, Reed J, Engelsberg A, Hariharan S, Kasturi V
- Issue date: 2020 Apr
- Real-world clinical outcomes with first-line avelumab in locally advanced/metastatic Merkel cell carcinoma in the USA: SPEAR-Merkel.
- Authors: Cowey CL, Liu FX, Kim R, Boyd M, Fulcher N, Krulewicz S, Kasturi V, Bhanegaonkar A
- Issue date: 2021 Jun